LENZ Therapeutics, Inc.

LENZ Nasdaq CIK: 0001815776

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH, CA, 92075
Mailing Address 201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH, CA, 92075
Phone 858-925-7000
Fiscal Year End 1231
EIN 844867570

Financial Overview

FY2025

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 30, 2026 View on SEC
4 Insider stock transaction report March 30, 2026 View on SEC
4 Insider stock transaction report March 30, 2026 View on SEC
8-K Current report of material events March 24, 2026 View on SEC
10-K Annual financial report March 24, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 5, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment January 21, 2026 View on SEC
8-K Current report of material events January 7, 2026 View on SEC
4 Insider stock transaction report January 6, 2026 View on SEC

Annual Reports

10-K March 24, 2026
  • FDA approval of flagship product VIZZ® achieved on July 31, 2025.
  • Successful transition from research-focused lab to commercial business.
View Analysis

Insider Trading

BUY 3 insiders 3 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.